Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $56.71

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $56.7143.

Several research analysts have commented on the stock. Jefferies Financial Group downgraded shares of Immunocore from a “buy” rating to a “hold” rating and decreased their price target for the stock from $48.00 to $33.00 in a research note on Monday, March 16th. Zacks Research raised shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, May 7th. Needham & Company LLC boosted their price target on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. Finally, Mizuho set a $38.00 price objective on Immunocore in a research note on Thursday, February 19th.

Immunocore Stock Up 0.2%

Shares of NASDAQ:IMCR opened at $28.60 on Friday. The firm has a market capitalization of $1.45 billion, a PE ratio of -52.00 and a beta of 0.74. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. Immunocore has a 52-week low of $27.56 and a 52-week high of $40.71. The firm has a fifty day moving average of $29.38 and a 200 day moving average of $31.96.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.51. The firm had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 earnings per share. As a group, research analysts anticipate that Immunocore will post 0.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunocore

Large investors have recently bought and sold shares of the stock. Harbour Investments Inc. lifted its position in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the last quarter. DNB Asset Management AS grew its holdings in shares of Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock worth $295,000 after purchasing an additional 488 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after buying an additional 572 shares during the period. R Squared Ltd raised its holdings in Immunocore by 7.4% during the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after buying an additional 606 shares during the last quarter. Finally, Leonteq Securities AG bought a new stake in Immunocore during the 4th quarter valued at $30,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.